Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation

Gitte Berkers, Renske van der Meer, Harry Heijerman, Jeffrey M Beekman, Sylvia F Boj, Robert G J Vries, Peter van Mourik, Jamie R Doyle, Paul Audhya, Zheng Jason Yuan, Nils Kinnman, C Kors van der Ent

Research output: Contribution to journalArticleAcademicpeer-review

14 Downloads (Pure)

Abstract

BACKGROUND: Previous in vitro organoid data showed A455E-CFTR, a rare CFTR mutation with 4.1% prevalence in the Netherlands, responds to lumacaftor/ivacaftor (LUM/IVA). We explored LUM/IVA's clinical efficacy in people with CF and ≥1 A455E-CFTR mutation.

METHODS: Participants aged ≥12 years were randomized to 1 of 2 treatment sequences (LUM/IVA→placebo or placebo→LUM/IVA) with an 8-week washout period between. Primary endpoint was absolute change in ppFEV1 from study baseline through 8 weeks. Additional endpoints were change in sweat chloride concentration (SwCl) and CFQ-R respiratory domain score. Correlations between organoid-based measurements and clinical endpoints were investigated.

RESULTS: Twenty participants were randomized at 2 sites in the Netherlands. Mean absolute change in ppFEV1 from study baseline through Week 8 showed a treatment difference of 0.1 percentage points (95% CI, -2.5 to 2.7; P = 0.928) between LUM/IVA (within-group mean change, 2.7) and placebo (within-group mean change, 2.6). The mean absolute change in SwCl concentration from study baseline through Week 8 showed a treatment difference of -7.8 mmol/L between LUM/IVA and placebo (P = 0.004), while the absolute change in CFQ-R respiratory domain score showed a treatment difference of 3.5 between LUM/IVA and placebo (P = 0.469). The in vitro organoid-based assay demonstrated a concentration-dependent swelling increase with LUM/IVA. Exploratory correlation analyses between organoid swelling and ppFEV1 and SwCl outcomes showed correlation coefficients of 0.49 and -0.11, respectively.

CONCLUSIONS: In this exploratory study, LUM/IVA elicited an in vitro response in organoid swelling and in vivo response in SwCl in participants with CF and ≥1 A455E-CFTR mutation. The primary endpoint (ppFEV1) did not show a statistically significant difference between LUM/IVA and placebo; correlations between in vitro and in vivo responses were not established (NCT03061331).

Original languageEnglish
Pages (from-to)761-767
Number of pages7
JournalJournal of Cystic Fibrosis
Volume20
Issue number5
Early online date25 Nov 2020
DOIs
Publication statusPublished - Sept 2021

Keywords

  • A455E–CFTR
  • Crossover study
  • Cystic fibrosis
  • Lumacaftor/ivacaftor

Fingerprint

Dive into the research topics of 'Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation'. Together they form a unique fingerprint.

Cite this